The initial participant in a clinical trial for an experimental Ebola vaccine is Ed Hunt, a 37-year-old from the United Kingdom. Hunt volunteered after learning about an Ebola outbreak affecting the Democratic Republic of Congo. The vaccine was developed at the University of Oxford using the same technological platform that underlies one of the nation’s Covid-19 vaccines, and researchers completed the initial development in just eight weeks.
Hunt represents the first of 50 healthy volunteers aged 18-55 being enrolled in the trial. He stated that he had previously wanted to participate in a Covid vaccine trial but was unable to do so due to professional obligations. When he became aware of the outbreak in the Democratic Republic of Congo, he decided to contribute to the research effort.
The vaccine development benefited from extensive prior research spanning decades, according to Prof Teresa Lambe, who directs the Ebola vaccine team at Oxford. The initial phase of the clinical study will focus on evaluating vaccine safety and measuring immune response to determine whether it offers protective effects against the Bundibugyo species of Ebola. The vaccine cannot transmit Ebola to recipients. Four vaccines are currently under development for the Bundibugyo variant, with this Oxford candidate being the first to advance to human testing. An existing licensed vaccine addresses the Zaire species of Ebola but offers no protection against Bundibugyo.
The Oxford team has plans for additional trials, including a second small-scale study expected to launch in Uganda, followed by a larger efficacy trial in the Democratic Republic of Congo. The Serum Institute of India has already produced 600,000 doses of the Oxford vaccine in preparation for potential deployment if the trials demonstrate success. The outbreak in the Democratic Republic of Congo has resulted in more than 2,500 confirmed cases to date, with just over 1,000 deaths reported.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI